Highlights

  • AI shares surged 41.46% to AUD 0.058 on 29 April 2026 following Acquisition announcement.
  • Company entered agreement to acquire 100% of Singapore-based Chipforge.
  • Chipforge platform aims to reduce chip design timelines from 12–24 months.
  • Transaction includes 560 million shares and 150 million performance rights.
  • No Capital raising planned, with existing cash of approximately AUD 3.26 million.

Pathkey.AI Ltd (ASX:PKY) shares climbed 41.46% to AUD 0.058 during the morning session on 29 April 2026, extending its favourable momentum with gains of approximately 190% over the past year. The sharp move in the share price follows the company’s announcement that it has entered into a binding agreement to acquire an artificial intelligence-driven semiconductor design and verification platform, marking an expansion into a new technology segment.

Pathkey.AI Ltd is an Australian technology company focused on artificial intelligence applications across data-intensive industries. Its core platform, TrialKey, is designed to process large volumes of unstructured data and convert them into structured inputs for predictive modelling and optimisation. The company has primarily applied this technology within clinical trial design and optimisation, and is now expanding its scope into semiconductor engineering.

Acquisition of Chipforge Signals Strategic Expansion

The company announced that it has entered into a binding share purchase agreement to acquire 100% of Singapore-based Chipforge Pte Ltd. The agreement provides Pathkey with an irrevocable option to complete the Acquisition, exercisable within two months, with the possibility of extending the option period by an additional two months upon payment of a fee.

Completion of the transaction remains subject to several conditions, including Due Diligence, regulatory approvals, and Shareholder approval. The company expects the Acquisition to complete prior to the end of FY26, subject to these conditions being satisfied.

The consideration for the Acquisition includes the issuance of 560,000,000 fully paid ordinary shares and 150,000,000 performance rights. The performance rights are linked to specific milestones, including the development of a minimum viable product and the execution of a commercial agreement generating Revenue.

In addition, the company will assume and repay up to AUD 500,000 in Debt associated with Chipforge upon completion.

Chipforge Platform Targets Semiconductor Design Bottlenecks

Chipforge is developing an AI-powered semiconductor design platform aimed at addressing key challenges in chip development. The platform focuses on automating the translation of high-level design intent into hardware code, as well as verifying the functionality of that design.

Traditional chip design processes can take between 12 to 24 months and involve substantial costs, often running into millions of dollars. A significant portion of this timeline and cost is associated with verification processes, which can account for more than half of total project expenditure.

Chipforge’s platform applies AI agents across the design workflow, enabling users to input specifications and generate hardware designs, test them, and validate their functionality through automated processes. The system also progresses designs toward implementation on programmable hardware, with a roadmap extending toward full application-specific integrated circuit development.

The platform is supported by an exclusive, worldwide licence agreement with Ntuitive Pte Ltd, linked to Nanyang Technological University in Singapore. This agreement grants Chipforge rights to develop and commercialise products based on the licensed intellectual property, subject to meeting certain development and commercialisation milestones.

Strategic Rationale and Technology Synergies

The Acquisition aligns with Pathkey’s broader strategy of expanding its AI capabilities into adjacent sectors. Both the TrialKey platform and the Chipforge system are built on agent-based AI architectures, incorporating large language models and iterative optimisation processes.

While TrialKey applies these capabilities to clinical trial design, Chipforge applies a similar framework to semiconductor design. In both cases, AI agents generate potential solutions, evaluate them against defined parameters, and refine outputs through iterative processes.

The company highlighted that knowledge and technical developments from each platform can be applied across both systems. For example, methodologies used in structuring unstructured data within TrialKey may be applied to managing semiconductor design workflows and verification processes.

The Acquisition also extends Pathkey’s application of AI from healthcare into engineering and semiconductor development, introducing exposure to a sector with growing Demand driven by artificial intelligence, data infrastructure, and computing workloads.

Funding Position and Capital Allocation

Pathkey reported a cash position of approximately AUD 3.26 million as at 31 March 2026, with an expectation of receiving approximately AUD 840,000 in Research and Development rebates and other income over the next 12 months.

The company indicated that no Capital raising is currently planned in connection with the Acquisition. Based on its existing resources and expected inflows, the company believes it has sufficient funding to support development activities and working Capital requirements over the next year.

Over the next 12 months, Pathkey plans to allocate approximately AUD 4.1 million across its operations. This includes AUD 1.55 million for development of the TrialKey platform, AUD 1.5 million for the Chipforge platform, AUD 700,000 for working Capital and administration, and AUD 350,000 for transaction-related costs.

The company also noted that technological developments in one platform may contribute to the other, indicating that the overall Investment impact may extend beyond the direct allocation figures.

Operational Plans Post-Acquisition

Following completion of the Acquisition, Pathkey intends to continue operating the TrialKey platform from Australia, while Chipforge will remain based in Singapore.

Development efforts for both platforms will focus on enhancing technical capabilities and expanding commercial opportunities. For TrialKey, this includes improvements in predictive modelling, dataset expansion, and platform scalability.

For Chipforge, planned activities include building the core platform, developing AI-based design translation capabilities, and delivering automated verification workflows. The company also plans to establish pilot deployments and engage with universities and engineering programs to support development and validation.

The company outlined a proposed timetable, with Shareholder approvals expected by mid-June 2026 and completion targeted shortly thereafter, subject to conditions being met.

What This Means for Investors?

The announcement of the Chipforge Acquisition represents a strategic development for Pathkey, expanding its AI applications into semiconductor design and engineering workflows. The scale of the share price movement suggests that the market is responding to the potential implications of this expansion.

The transaction introduces new technological capabilities and exposure to a different sector, while also involving a significant issuance of shares and performance-based securities.

At the same time, completion of the Acquisition remains subject to conditions, including Due Diligence and approvals. The outcome of these processes, along with progress against development milestones, may influence how the transaction is assessed over time.

With a defined funding plan and no immediate Capital raising anticipated, the company’s focus is expected to remain on execution, platform development, and progression toward commercial outcomes across both TrialKey and Chipforge.